Early observations and pilot data that first suggested a new direction
Severely injured patients often present with coagulopathy and need massive transfusion, and some proposed early, aggressive correction with a 1:1 ratio of plasma to red blood cells (RBCs). In 2007, Borgman and colleagues reviewed 246 patients who received at least 10 RBC units in 24 hours at a US Army combat support hospital. Overall mortality was 65%, 34% and 19% with low (median 1:8), medium (1:2.5) and high (1:1.4) plasma:RBC ratios (p<0.001), and a high ratio was independently associated with survival (OR 8.6, 95% CI 2.1-35.2), mainly through fewer hemorrhage deaths. The authors advised a 1:1 plasma:RBC ratio in massive transfusion protocols for hypocoagulable patients with traumatic injuries.
Landmark RCTs and pivotal trials that established the evidence base
PROPPR randomized 680 severely injured patients predicted to require massive transfusion to plasma:platelets:RBC ratios of 1:1:1 or 1:1:2. Mortality did not differ significantly at 24 hours (12.7% versus 17.0%, P=.12) or 30 days (22.4% versus 26.1%, P=.26). More patients achieved hemostasis with 1:1:1 (86% versus 78%, P=.006), and 24-hour exsanguination deaths were fewer (9.2% versus 14.6%, P=.03). The trial found no differences in the 23 prespecified complications despite greater plasma and platelet use; it did not establish faster hemostasis or worldwide adoption.
Follow-up studies, subgroup analyses, and real-world validation
Two major extensions have refined massive transfusion practice. First, whole blood has re-emerged as a resuscitation product: low-titer group O whole blood provides balanced hemostatic resuscitation in a single product, simplifying logistics. The randomized T-STORHM trial was designed in 2019 to compare it with component therapy for in-hospital management of trauma patients with massive hemorrhage. Second, viscoelastic hemostatic assays (TEG and ROTEM) have enabled goal-directed transfusion, allowing clinicians to identify specific coagulation deficits and target therapy rather than empirically transfusing fixed ratios. The ITACTIC trial compared viscoelastic-guided with conventional test-guided algorithms and found no difference in 28-day mortality; in a secondary analysis of 133 patients, only 54% received goal-directed treatment and only 20% corrected their coagulopathy.
Integration into clinical practice guidelines and recommendations
The European bleeding guideline, sixth edition, recommends two initial strategies for expected massive hemorrhage: fibrinogen concentrate or cryoprecipitate plus RBCs, or FFP with an FFP:RBC ratio ≥1:2 as needed (Grade 1C). Ongoing treatment should be goal-directed using laboratory tests and/or viscoelastic monitoring. Early activation before laboratory confirmation remains a clinical consideration; fixed-ratio survival data are equivocal.
European guideline on management of major bleeding and coagulopathy following trauma, sixth edition
Expected massive hemorrhage: FFP:RBC ≥1:2 as needed or fibrinogen/cryo plus RBCs (Grade 1C); guide ongoing therapy by laboratory tests/VEM.
Current standard of care and ongoing research directions
European guidance combines an initial expected-massive-hemorrhage strategy with goal-directed refinement. T-STORHM was designed to compare low-titer group O whole blood with components in hospital trauma care; its design paper reports no results. CRYOSTAT-2 tested early empirical high-dose cryoprecipitate added to standard care: 28-day mortality was 25.3% versus 26.1% (OR 0.96, 95% CI 0.75–1.23), without benefit. This differs from deficit-guided fibrinogen replacement. Questions include prehospital delivery, dried plasma, artificial oxygen carriers and whether machine learning can predict transfusion need.
What is the evidence for 1:1:1 versus 1:1:2 blood product ratios?+
The PROPPR trial (2015) randomized 680 severely injured patients predicted to need massive transfusion to 1:1:1 versus 1:1:2 (plasma:platelets:RBCs). Mortality did not differ at 24 hours (12.7% vs 17.0%, P=.12) or 30 days (22.4% vs 26.1%, P=.26), but more 1:1:1 patients achieved hemostasis (86% vs 78%, P=.006) and fewer died of exsanguination by 24 hours (9.2% vs 14.6%, P=.03). None of 23 prespecified complications, including ARDS and transfusion-related complications, differed.
When should a massive transfusion protocol be activated?+
In a retrospective study of 596 adults, ABC ≥2 predicted massive transfusion (75% sensitivity, 86% specificity); inputs were penetrating mechanism, positive FAST, SBP ≤90 mmHg and HR ≥120/min. The European trauma guideline recommends combining physiology, anatomical injury, mechanism and response to resuscitation, rather than relying on a single predictor. Activate promptly when clinically indicated; confirm local thresholds.
What is the role of whole blood in trauma resuscitation?+
Low-titer group O whole blood provides balanced resuscitation (RBCs, plasma, platelets, and clotting factors) in a single product, which may simplify component-delivery logistics. The randomized T-STORHM trial was designed to compare low-titer group O whole blood with component therapy in the in-hospital management of trauma patients with massive hemorrhage.
How do viscoelastic assays (TEG/ROTEM) change transfusion management?+
Use early, repeated laboratory and/or viscoelastic monitoring to guide coagulation treatment. The European trauma guideline recommends goal-directed resuscitation (Grade 1B), FFP for demonstrated factor deficiency, and fibrinogen concentrate or cryoprecipitate for major bleeding with functional fibrinogen deficit or Clauss fibrinogen ≤1.5 g/L. It suggests platelets to maintain counts above 50 × 10⁹/L in ongoing bleeding, or 100 × 10⁹/L with TBI. TXA administration should not await viscoelastic results. Assay choice alone does not guarantee a mortality benefit.